| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/500-1/1000 | Human,Mouse,Rat |
| Aliases | NGFB; HSAN5; Beta-NGF |
| WB Predicted band size | 27 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human NGF |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NGF抗体的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee*
**作者**：Lane NE, et al.
**摘要**：该临床试验评估了抗NGF单克隆抗体Tanezumab在膝骨关节炎患者中的疗效与安全性。结果显示，与安慰剂相比，Tanezumab显著减轻疼痛并改善关节功能，但部分患者出现关节异常(如骨坏死)，提示需权衡疗效与潜在风险。
2. **文献名称**：*Anti-NGF Therapy for Pain and Neurodegenerative Disorders*
**作者**：Mantyh PW, et al.
**摘要**：本文综述了抗NGF抗体在慢性疼痛(如神经性疼痛、炎症性疼痛)和神经退行性疾病中的机制。临床前研究表明，阻断NGF可有效抑制疼痛信号通路，但在神经保护方面的作用仍需进一步研究。
3. **文献名称**：*NGF and Its Role in Alzheimer’s Disease: A Study on Antibody Intervention*
**作者**：Hefti F, et al.
**摘要**：研究探讨了NGF抗体在阿尔茨海默病模型中的作用，发现抑制NGF会加剧胆碱能神经元退化，提示NGF对神经元存活至关重要，而抗体的不当使用可能加速病理进程。
---
如需更多文献或具体研究方向(如癌症疼痛)，可进一步补充说明。
**Background of NGF Antibodies**
Nerve Growth Factor (NGF), a member of the neurotrophic factor family, plays a critical role in the survival, differentiation, and maintenance of sensory and sympathetic neurons. Discovered in the 1950s, NGF binds to tropomyosin receptor kinase A (TrkA) and the p75 neurotrophin receptor (p75NTR), activating signaling pathways that regulate neuronal development and plasticity. Beyond its physiological functions, NGF is implicated in pathological conditions, including chronic pain, inflammation, and neurodegenerative diseases. Elevated NGF levels are associated with hyperalgesia and allodynia, making it a therapeutic target.
NGF antibodies are monoclonal or polyclonal antibodies designed to neutralize NGF activity. By blocking NGF-TrkA interactions, these antibodies inhibit downstream pro-inflammatory and pain-signaling pathways. Preclinical studies highlight their potential in alleviating pain in osteoarthritis, chronic lower back pain, and cancer-induced bone pain. Clinical trials, particularly with anti-NGF agents like tanezumab, have shown efficacy in reducing pain and improving function in patients unresponsive to conventional analgesics.
However, safety concerns, including rare cases of rapidly progressive osteoarthritis or peripheral neuropathy, have prompted cautious clinical development. Ongoing research aims to optimize dosing and identify patient subgroups most likely to benefit. NGF antibodies represent a promising class of biologics for chronic pain management, bridging gaps in current therapeutics while underscoring the need for balanced risk-benefit evaluation.
×
